Do not use in pregnant animals since Galastop® may cause abortion. Do not use in lactating bitches unless suppression of lactation is required.

Galastop® may induce transient hypotension in treated animals. Do not use in animals concurrently being treated with hypotensive drugs. Do not use directly after surgery whilst the animal is still under the influence of the anaesthetic agents.

Since cabergoline exerts its therapeutic effect by direct stimulation of dopamine receptors, Galastop® should not be administered concurrently with drugs which have dopamine antagonist activity (such as phenothiazines, butyrophenones), as these might reduce its prolactin inhibiting effects.

Vomiting or anorexia may occur after the first one or two doses in a small proportion of cases. There is no need to discontinue treatment unless vomiting is severe or it persists beyond the second dose.

In some animals a degree of drowsiness may be seen in the first 2 days of dosing.

The experimental data indicate that a single overdose with Galastop® might result in an increased likelihood of post-treatment vomiting, and possibly an increase in post-treatment hypotension. General supportive measures should be undertaken to remove any unabsorbed drug and maintain blood pressure, if necessary. It is unlikely that the administration of dopamine antagonist drugs would be necessary, but this course of action could be considered.

For animal treatment only. Keep out of reach and sight of children.